💨 Abstract

Insmed Inc. (INSM) reported a first-quarter loss of $256.6 million, or $1.42 per share, missing Wall Street's expected loss of $1.36 per share. Despite the loss, the biopharmaceutical company exceeded revenue forecasts, generating $92.8 million, slightly above the projected $92.7 million. Insmed focuses on developing inhaled treatments for rare lung diseases.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖